ALID 11
Alternative Names: ALID-11Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Allied Corp
- Developer Allied Corp; Argent BioPharma
- Class Anxiolytics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Post-traumatic stress disorders
Highest Development Phases
- No development reported Post-traumatic stress disorders
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in Canada
- 31 Aug 2020 Allied Corp files for provisional patent application with United States Patent and Trademark Office for ALID 11 in USA
- 26 Jun 2020 ALID 11 is available for licensing as of 26 Jun 2020. https://allied.health/pharmaceutical/#clinical